News
The Alzheimer's Association is urging patients, caregivers, and advocates to "take action now" and support legislation this ...
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...
I recently visited Washington, D.C., and it was cold — perhaps not by the standards of northern states, but bitter compared with my home in South Florida. Now, I’ve been colder in my life, but the ...
Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in ...
The U.S. Food and Drug Administration (FDA) has approved BrainSee, Darmiyan’s software for predicting the likelihood that a person with mild cognitive impairment (MCI) will progress to Alzheimer’s ...
Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) significantly slows cognitive and functional decline in people with early Alzheimer’s disease, according to a new data ...
There’s still life to live, however, and friends, family, and caregivers are integral to living the best life possible after a diagnosis. A fourth of all Americans 65 and older who live in communities ...
Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...
Cognitive benefits were reported in nearly half of the Alzheimer’s disease patients given simufilam for one year in a clinical trial, while those with early-stage, mild disease appeared to respond ...
Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...
Intranasal, or into-the-nose, delivery of foralumab, an investigational antibody-based treatment being developed by Tiziana Life Sciences, restored the activity of microglial cells and improved ...
Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results